United States

US Congress
#Investment #Politics #United States #US Food and Drug Administration (FDA)

After the midterms, biopharma needs more than a policy forecast

A Democratic Congress will likely sharpen oversight of the FDA and drug pricing, but the most consequential choices for drug developers in 2027 will still be made in clinical trial protocols, financing plans and portfolio reviews.  Washington has had a leadership change, but the development equation… Read More

#Exclusive Content #Opinion

US science protest
#Drug discovery #Funding #National Institutes of Health (NIH) #Politics #United States

Researchers challenge NIH screening of scientific research grants

US researchers have filed a class action lawsuit challenging the National Institutes of Health’s (NIH) policy of blocking grants to censor views it disagrees with, on everything from DEI to gender identity to climate change.  The plaintiffs are represented by the American Civil Liberties Union, the ACLU… Read More

#Editor's Choice #News #Trending News

FDA headquarters
#Biopharma #Drug development #FDA #Interview #Regulatory #United States

Is it harder to align with FDA expectations within pharma in 2026?  

DDW Editor Reece Armstrong speaks to David Crean, Chief Business Officer of biopharmaceutical company MediciNova, about recent turmoil within the FDA and what the pharma sector should expect from the agency going forward.  It’s been a volatile couple of years for the United States. President Trump’s second term… Read More

#Exclusive Content

Bacteria in Petri dishes
#Antimicrobial resistance (AMR) #United States

AMR Bio confirms contribution to US National Action Plan 

Biotechnology company AMR Bio has submitted written comments in efforts to shape the US National Action Plan to combat antibiotic-resistant bacteria.  AMR Bio wrote to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) ahead of the council’s 27th public meeting on 16 June 2026, contributing to the next iteration… Read More

#News

#Cyber security #Lab automation #United States

Preparing for cyber-risks in the lab

Dr Marc Porr, Founder and CEO of TechkIT, examines the cyber-security risks that have reached the automated lab.  About a year ago Mark Auty from Unilever wrote about new cyber security challenges arising… Read More

#Exclusive Content

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK #United States

This week in Drug Discovery (9 – 13 February) 

News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW.  This week in DDW, researchers have made a key discovery into cancer survival. Elsewhere, a global research effort into kidney disease is underway.  The top stories:    Researchers identify RNA linked to cancer… Read More

#News

#AI #Drug discovery #United States

From the Editor: A year in turmoil

For the drug discovery, and wider pharmaceutical industry, the year of 2025 can be characterised by the words turmoil and uncertainty.   The second coming of President Trump brought with it a flurry of executive orders, tariffs and global bargaining that placed the US in a position… Read More

#Exclusive Content #Opinion

#GlobalData #Investment #Pharmaceutical industry #Politics #Tariffs #UK #United States

Is US foreign policy uncertainty strengthening confidence in the UK?

The recent UK-US policy developments are reshaping global pharmaceutical investment and launch strategies, according to intelligence platform GlobalData.  In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines and medical technologies tariff-free access to the US market for… Read More

#Business & Investment #News #Trending News

#AstraZeneca #Biopharma #Direct-to-Consumer #Pfizer #Pharmaceutical industry #United States

Pharma firms offer discounts of up to 85% to US patients

AstraZeneca has become the latest company to lower the cost of medicines for American patients. The company recently announced an agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients “while preserving America’s cutting-edge biopharmaceutical innovation”.  In July, US President Donald… Read More

#Business & Investment #Editor's Choice #News

Healthy cells
#CAR-T #Cell therapy #FDA #United States

FDA cracks down on overseas cell processing for clinical trials

The US Food and Drug Administration (FDA) has prohibited new clinical trials that send US patients’ live cells overseas, including to China, for gene editing and return infusion.   While the scope and impact are unclear, smaller cell and gene therapy companies that rely on foreign manufacturing may… Read More

#News

Johnson & Johnson head office
#Investment #Johnson & Johnson #Manufacturing #New facility #United States

Johnson & Johnson continues US manufacturing investment

Johnson & Johnson has revealed plans to increase its presence in North Carolina with a dedicated manufacturing facility at FUJIFILM’s new biopharmaceutical manufacturing site in Holly Springs, North Carolina.   The $2 billion commitment to FUJIFILM over the next 10 years will expand the company’s US manufacturing capacity… Read More

#Business & Investment #News